| Latest Cadence Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 11/13/2009 | 7:30AM | PRNUS | Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
SAN DIEGO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen... More...>> |
| 11/05/2009 | 4:01PM | PRNUS | Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended... More...>> |
| 10/28/2009 | 6:00PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on N
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder... More...>> |
| 10/20/2009 | 5:00PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder... More...>> |
| 08/04/2009 | 5:30PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 1
SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 07/15/2009 | 7:00AM | PRNUS | Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pai
SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing... More...>> |
| 06/04/2009 | 7:50PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 05/14/2009 | 7:00AM | PRNUS | Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for the treatment of acute pain... More...>> |
| 05/07/2009 | 4:01PM | PRNUS | Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31... More...>> |
| 05/05/2009 | 4:15PM | PRNUS | Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 04/30/2009 | 5:39PM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March... More...>> |
| 04/27/2009 | 8:30AM | PRNUS | Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that data from clinical trials of its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 34th... More...>> |
| 03/26/2009 | 4:01PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industr
SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 03/12/2009 | 4:15PM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and C
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year... More...>> |
| 03/12/2009 | 4:01PM | PRNUS | Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results and Provides Corporate and Clinical Updates
Acetavance(TM) On Track for Second Quarter 2009 NDA Submission; Omigard(TM) Program Discontinued
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for... More...>> |
| 03/09/2009 | 9:35PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Cowen & Company's 29th Annual Health Care Conference in Boston on
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |
| 03/05/2009 | 4:15PM | PRNUS | Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and C
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year... More...>> |
| 02/19/2009 | 7:30AM | PRNUS | Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that it completed its previously announced private placement of approximately 12 million shares of the Company's common stock at a price of $7.13 per share and five-year warrants to purchase up to approximately 6... More...>> |
| 02/17/2009 | 8:30AM | PRNUS | Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) announced today that it has entered into an agreement to issue and sell in a private placement approximately 12 million shares of the Company's common stock and warrants to purchase up to approximately 6 million additional shares... More...>> |
| 02/10/2009 | 4:30PM | PRNUS | Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ:CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder... More...>> |